IP Library › Granted Patent US 12,493,049
Granted Patent B2
US 12,493,049 · App. 18/760,381 · Granted Dec 9, 2025

Quantitation of insulin-like growth factor-I and insulin-like growth factor-II with high-resolution mass spectrometry

Inventors: Cory Bystrom (Beachwood, OH); Shijun Sheng (Las Flores, CA); Nigel Clarke (Vista, CA); Richard Reitz (San Clemente, CA)
Assignee: Quest Diagnostics Investments Incoporated
G01N33/74G01N33/6848
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,493,049
App. No.
18/760,381
Granted
Dec 9, 2025
Kind
B2
Abstract

A method of determining the amount of an IGF-I and/or IGF-II protein in a sample using high resolution/high accuracy mass spectrometry includes enriching an IGF-I and/or IGF-II protein in a sample, ionizing an IGF-I and/or IGF-II protein from the sample to generate IGF-I and/or IGF-II protein ions, and determining the amount of IGF-I and/or IGF-II protein ions with high resolution/high accuracy mass spectrometry.

Claims (20)

1 . A method for determining an amount of an insulin-like growth factor-I (IGF-I) protein in a serum or plasma sample, the method comprising:

subjecting IGF-I protein in the sample to ionization by electron ionization, chemical ionization, electrospray ionization, photon ionization, atmospheric pressure chemical ionization, photoionization, atmospheric pressure photoionization, fast atom bombardment, liquid secondary ionization, matrix assisted laser desorption ionization, field ionization, field desorption, thermospray/plasmaspray ionization, surface enhanced laser desorption ionization, inductively coupled plasma, or particle beam ionization to produce one or more IGF-I ions detectable by mass spectrometry;

determining an amount of the one or more IGF-I ions by high resolution/high accuracy mass spectrometry with a mass analyzer capable of a resolving power of full width at half maximum (FWHM) of greater than or equal to 10,000 and an accuracy of less than or equal to 50 ppm; and

determining the amount of the IGF-I protein based on the amount of the one or more IGF-I ions, wherein the one or more IGF-I ions are in a 6+, 7+, 8+, or 9+ charge state.

2 . The method of claim 1 , wherein the IGF-I protein is an intact IGF-I protein or a fragment with a molecular weight of 1,000 Daltons or larger.

3 . The method of claim 1 , wherein the IGF-I protein is intact long R3 IGF-I or a fragment with a molecular weight of 1,000 Daltons or larger thereof.

4 . The method of claim 1 for determining the amount of the IGF-I protein, wherein the one or more IGF-I ions detectable by mass spectrometry comprise one or more ions selected from a group consisting of ions with mass to charge ratios within ranges of 850.8±2, 957.1±2, 1093.7±2, and 1275.8±2, or

wherein the one or more IGF-I ions detectable by mass spectrometry comprise one or more ions selected from a group consisting of ions with mass to charge ratios within ranges of 850.8±1, 957.1±1, 1093.7±1, and 1275.8±1, or

wherein the one or more IGF-I ions detectable by mass spectrometry comprise one or more ions selected from a group of ions with a mass to charge ratio of 1091.9447±0.1, 1092.8031±0.1, 1092.9445±0.1,1093.0881±0.1, 1093.2308±0.1,1093.3740±0.1,1093.5167 ±0.1, 1093.6597±0.1, 1093.8028±0.1, 1093.9458±0.1, 1094.0889±0.1, 1094.2319±0.1, 1094.3754±0.1, 1094.5185±0.1, 1094.6606±0.1, and 1095.3717±0.1.

5 . The method of claim 1 , wherein the IGF-I protein is a human IGF-I protein.

6 . The method of claim 1 , wherein the IGF-I protein is native to the sample, and/or wherein the IGF-I protein is an intact IGF-I protein.

7 . The method of claim 1 , wherein the IGF-I protein is chemically modified prior to ionization.

8 . The method of claim 7 , wherein the chemical modification comprises reduction of one or more disulfide bridges in the IGF-I protein, or wherein the chemical modification comprises alkylation of one or more cysteines in the IGF-I protein.

9 . The method of claim 7 , wherein the sample is further purified by HPLC and/or SPE prior to ionization and said SPE and/or HPLC are conducted with on-line processing.

10 . The method of claim 1 , wherein the IGF-I protein from said sample is purified with solid phase extraction (SPE) prior to ionization, and/or wherein the IGF-I protein from said sample is purified by high performance liquid chromatography (HPLC) prior to ionization.

11 . The method of claim 1 , wherein the high resolution/high accuracy mass spectrometry is conducted with an orbitrap mass spectrometer or with a time of flight mass spectrometer, or with an orbitrap or time of flight mass analyzer capable of a FWHM of greater than or equal to 20,000 and an accuracy of less than or equal to 10 ppm, or with an orbitrap or time of flight mass analyzer capable of a FWHM of greater than or equal to 20,000 and an accuracy of less than or equal to 5 ppm.

12 . The method of claim 1 , wherein the determining the amount of one or more IGF-I ions comprises collecting spectrometric data from one or more peaks with each peak resulting from an isotopic form of an ion.

13 . The method of claim 12 , wherein two or more peaks each resulting from a different isotopic form of an ion are used to confirm the identity of the IGF-I protein, or wherein spectrometric data from a peak resulting from a single isotopic form is used to determine the amount of the IGF-I protein in the sample, or wherein spectrometric data from two or more peaks each resulting from a different isotopic form are used to determine the amount of the IGF-I protein in the sample.

14 . The method of claim 1 , wherein the sample comprises a biological fluid, or wherein the sample comprises plasma or serum.

15 . The method of claim 1 , wherein the one or more IGF-I ions detectable by mass spectrometry comprise one or more IGF-I ions in a 8+, 7+, 6+, or 5+ charge state.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2024
From: BYSTROM, CORY; SHENG, SHIJUN; CLARKE, NIGEL; REITZ, RICHARD
To: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
Reel/Frame 067887/0686 →
Continuity (8)
Continuation 18132009 · Apr 7, 2023
Continuation 17949863 · Sep 21, 2022
Continuation 16857628 · Apr 24, 2020
Continuation 15602764 · May 23, 2017
Continuation 12939996 · Nov 4, 2010
Provisional Application 61408535 · Oct 29, 2010
Provisional Application 61258560 · Nov 5, 2009
Related Publication 20240369581A1 · Nov 7, 2024
References Cited (95)
US 5772874A · Quinn et al. · 1998 [cited by applicant]
US 5795469A · Quinn et al. · 1998 [cited by applicant]
US 5851907A · Mohan et al. · 1998 [cited by applicant]
US 5919368A · Quinn et al. · 1999 [cited by applicant]
US 5968367A · Quinn et al. · 1999 [cited by applicant]
US 6107623A · Bateman et al. · 2000 [cited by applicant]
US 6124137A · Hutchens et al. · 2000 [cited by applicant]
US 6204500B1 · Whitehouse et al. · 2001 [cited by applicant]
US 6268144B1 · Koester · 2001 [cited by applicant]
US 6995364B2 · Makarov et al. · 2006 [cited by applicant]
US 10436803B2 · Chen et al. · 2019 [cited by applicant]
US 10648989B2 · Bystrom et al. · 2020 [cited by applicant]
US 20030218129A1 · Rather · 2003 [cited by applicant]
US 20040232327A1 · Bateman et al. · 2004 [cited by applicant]
US 20050032116A1 · Nelson et al. · 2005 [cited by applicant]
US 20060228808A1 · Clarke et al. · 2006 [cited by applicant]
US 20080064044A9 · Nelson et al. · 2008 [cited by applicant]
US 20080118932A1 · Toler et al. · 2008 [cited by applicant]
US 20080296486A1 · Blanksby et al. · 2008 [cited by applicant]
US 20090035807A1 · McCellan et al. · 2009 [cited by applicant]
US 20090054320A1 · Buchanan et al. · 2009 [cited by applicant]
US 20110111512A1 · Bystrom et al. · 2011 [cited by applicant]
US 20150355191A1 · Snel · 2015 [cited by examiner]
US 20170015749A1 · Stanimirovic · 2017 [cited by examiner]
US 20170022277A1 · Stanimirovic · 2017 [cited by examiner]
IE 913058A1 · 1992 [cited by applicant]
WO 2008057083A1 · 2008 [cited by applicant]
WO 2009018307A2 · 2009 [cited by applicant]
Abellan R., et al., Immunoassays for the Measurement of IGF-II, IGFBP-2 and -3, and ICTP as Indirect Biomarkers of Recombinant Human Growth Hormone Misuse in Sport, Journal of Pharmaceutical and Biomedical Analysis, 200… [cited by applicant]
Advisory Action mailed Mar. 12, 2024 for U.S. Appl. No. 18/132,009, filed Apr. 7, 2023. [cited by applicant]
Bantscheff M., et al., “Robust and Sensitive iTRAQ Quantification on an LTQ Orbitrap Mass Spectrometer,” Molecular and Cellular Proteomics, 2008, vol. 7 (9), pp. 1702-1713. [cited by applicant]
Bayne S.J., et al., “Confirming the Primary Structures of Insulin-Like Growth Factors 1 and 2 Isolated From Porcine Plasma Using Mass Analysis,” Peptide Research, 1990, vol. 3 (6), pp. 271-273. [cited by applicant]
Bayne S.J., et al., “Primary Sequences of Insulin-Like Growth Factors 1 and 2 Isolated from Porcine Plasma,” Journal of Chromatography, 1991, vol. 562 (1-2), pp. 391-402. [cited by applicant]
Bendall S., et al., “An Enhanced Mass Spectrometry Approach Reveals Human Embryonic Stem Cell Growth Factors in Culture,” Molecular Cellular Proteomics, 2009, vol. 8(3), pp. 421-432. [cited by applicant]
Bobin S., et al., “Approach to the Determination of Insulin-Like-Growth-Factor-I (IGF-I) Concentration in Plasma by High-Performance Liquid Chromatography-Ion Trap Mass Spectrometry: Use of a Deconvolution Algorithm for… [cited by applicant]
Bredehoft M., et al., “Quantification of Human Insulin-Like Growth Factor-1 and Qualitative Detection of Its Analogues in Plasma Using Liquid Chromatography/Electrospray Ionisation Tandem Mass Spectrometry,” Rapid Commu… [cited by applicant]
Bystrom C., et al., “Clinical Utility of Insulin-Like Growth Factor 1 and 2; Determination by High Resolution Mass Spectrometry,” PLOS One, 2012, vol. 7 (9), pp. e43457. [cited by applicant]
Bystrome C.E., et al., “Narrow Mass Extraction of Time-of-Flight Data for Quantitative Analysis of Proteins: Determination of Insulin-Like Growth Factor-1,” Analytical Chemistry, 2011, vol. 83 (23), pp. 9005-9010. [cited by applicant]
De Kock S.S., et al., “Growth Hormone Abuse in the Horse: Preliminary Assessment of a Mass Spectrometric Procedure for IGF-1 Identification and Quantitation,” Rapid Communications in Mass Spectrometry, 2001, vol. 15 (14… [cited by applicant]
European Office Action for Application No. EP10829122, mailed on Oct. 23, 2013, 4 pages. [cited by applicant]
Examiner's Answer to Appeal Brief mailed Mar. 3, 2016 for U.S. Appl. No. 12/939,996, filed Nov. 4, 2010. [cited by applicant]
Extended European Search Report for Application No. 10829122.0, mailed on Feb. 25, 2013. [cited by applicant]
Extended European Search Report for Application No. 24178089.9, mailed on Jul. 5, 2024, 19 Pages. [cited by applicant]
Extended European Search Report for Application No. EP16174510.4, mailed on Aug. 16, 2016, 13 pages. [cited by applicant]
Extended European Search Report for Application No. EP18168369.9, mailed on Jun. 28, 2018, 13 pages. [cited by applicant]
Final Office Action mailed Dec. 7, 2023 for U.S. Appl. No. 18/132,009, filed Apr. 7, 2023. [cited by applicant]
Final Office Action mailed Nov. 14, 2013 for U.S. Appl. No. 12/939,996, filed Nov. 4, 2010. [cited by applicant]
Final Office Action mailed Oct. 20, 2014 for U.S. Appl. No. 12/939,996, filed Nov. 4, 2010. [cited by applicant]
Hampton B., et al., “Purification and Characterization of Insulin-Like Growth Factor II Variant from Human Plasma,” The Journal of Biological Chemistry, 1989, vol. 264 (32), pp. 19155-19160. [cited by applicant]
Hardware Manual: API 4000™ LC/MS/MS System Part No. 5005565 A Apr. 2010. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2010/055518, mailed on May 18, 2012. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2010/055518, mailed on Jan. 14, 2011. [cited by applicant]
Jespersen S., et al., “Characterization of O-Glycosylated Precursors of Insulin-like Growth Factor II by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry,” Journal of Mass Spectrometry, 1996, vol. 31 (8), p… [cited by applicant]
Kiefer P., et al., “Quantitative Metabolome Analysis Using Liquid Chromatography-High-Resolution Mass Spectrometry,” Analytical Biochemistry, Nov. 2008, vol. 382 (2), pp. 94-100. [cited by applicant]
Kirsch S., et al., “Development of an Absolute Quantification Method Targeting Growth Hormone Biomarkers Using Liquid Chromatography Coupled to Isotope Dilution Mass Spectrometry,” Journal of Chromatography, 2007, vol. … [cited by applicant]
Le-Breton M.H., et al., “Direct Determination of Recombinant Bovine Somatotropin in Plasma from a Treated Goat by Liquid Chromatography/High-Resolution Mass Spectrometry,” Rapid Communications in Mass Spectrometry, 2008… [cited by applicant]
Mann M., et al., “Precision Proteomics: The Case for High Resolution and High Mass Accuracy,” Proceedings of the National Academy of Sciences of the United States of America, Nov. 2008, vol. 105 (47), pp. 18132-18138. [cited by applicant]
Mass Accuracy and Mass Resolution in TOF MS, by Agilent Technologies [Online], 2000. Retrieved from the Internet: [ http://www.chem.agilent.com/Library/eseminars/Public/Mass%20Accuracy%20and%20Mass%20Resolution%20- %200… [cited by applicant]
Merchant M., et al., “Recent Advancements in Surface-Enhanced Laser Desorption/Ionization-Time of Flight-Mass Spectrometry,” Electrophoresis, 2000, vol. 21 (6), pp. 1164-1167. [cited by applicant]
Moriyama S., et al., “Growth Regulation by Insulin-like Growth Factor-I in Fish,” Bioscience Biotechnology and Biochemistry, 2000, vol. 64(8), pp. 1553-1562. [cited by applicant]
Nedelkov D., et al., “Detection of Bound and Free IGF-1 and IGF-2 in Human Plasma via Biomolecular Interaction Analysis Mass Spectrometry,” FEBS Letters 2003, vol. 536, pp. 130-134. [cited by applicant]
Nelson R.E., et al., “Quantitative Mass Spectrometric Immunoassay of Insulin like Growth Factor 1,” Journal of Proteome Research, 2004, vol. 3 (4), pp. 851-855. [cited by applicant]
Non-Final Office Action and Amendment After Final or Under 37CFR 1.312, Initialed by the Examiner mailed Apr. 28, 2014 for U.S. Appl. No. 12/939,996, filed Nov. 4, 2010. [cited by applicant]
Non-Final Office Action mailed Sep. 4, 2019 for U.S. Appl. No. 15/602,764, filed May 23, 2017. [cited by applicant]
Non-Final Office Action mailed Nov. 16, 2018 for U.S. Appl. No. 15/602,764, filed May 23, 2017. [cited by applicant]
Non-Final Office Action mailed Mar. 19, 2013 for U.S. Appl. No. 12/939,996, filed Nov. 4, 2010. [cited by applicant]
Non-Final Office Action mailed Jan. 21, 2022 for U.S. Appl. No. 16/857,628, filed Apr. 24, 2020. [cited by applicant]
Non-Final Office Action mailed Jan. 22, 2016 for U.S. Appl. No. 14/063,956, filed Oct. 25, 2013. [cited by applicant]
Non-Final Office Action mailed Jul. 26, 2023 for U.S. Appl. No. 17/949,863, filed Sep. 21, 2022. [cited by applicant]
Non-Final Office Action mailed Aug. 31, 2023 for U.S. Appl. No. 18/132,009, filed Apr. 7, 2023. [cited by applicant]
Olsen J.V., et al., “Higher-Energy C-Trap Dissociation for Peptide Modification Analysis,” Nature Methods, 2007, vol. 4 (9), pp. 709-712. [cited by applicant]
Polson C., et al., “Optimization of Protein Precipitation Based Upon Effectiveness of Protein Removal and Ionization Effect in Liquid Chromatography-Tandem Mass Spectrometry,” Journal of Chromatography B, 2003, vol. 785… [cited by applicant]
Popot M.A., et al., “Determination of IGF-I in Horse Plasma by LC Electrospray Ionization Mass Spectrometry,” Analytical and Bioanalytical Chemistry, 2008, vol. 390 (7), pp. 1843-1852. [cited by applicant]
Popot M.A., et al., “High Performance Liquid Chromatography-Ion Trap Mass Spectrometry for the Determination of Insulin-Like Growth Factor-I in Horse Plasma,” Chromatographia, 2001, vol. 54, pp. 737-741. [cited by applicant]
Rousu T., et al., “Comparison of Triple Quadrupole, Hybrid Linear Ion Trap Triple Quadrupole, Time-Of-Flight and LTQ-Orbitrap Mass Spectrometers in Drug Discovery Phase Metabolite Screening and Identification in Vitro—A… [cited by applicant]
Russell D.H., et al., “High Resolution Mass Spectrometry and Accurate Mass Measurements with Emphasis on the Characterization of Peptides and Proteins by Matrix assisted Laser Desorption Ionization Time of flight Mass S… [cited by applicant]
Schenk S., et al., “A High Confidence, Manually Validated Human Blood Plasma Protein Reference Set,” BMC Medical Geonomics, 2008, vol. 1, pp. 41. [cited by applicant]
Scigelova M., et al., “Orbitrap Mass Analyzer—Overview and Applications in Proteomics,” PractProteo, 2006, vol. 1 (2), pp. 16-21. [cited by applicant]
Significant Figures and Errors: courses.chem.psu.edu/chem110h/errors.pdf. [cited by applicant]
Smith M.C., et al., “Structure and Activity Dependence of Recombinant Human Insulin-Like Growth Factor II on Disulfide Bond Pairing,” The Journal of Biological Chemistry, 1989, vol. 264 (16), pp. 9314-9321. [cited by applicant]
Straczek J., et al., “Purification and Characterization of Three Molecular Forms of Insulin-like Growth Factor II From Human Cohn Paste IV,” Journal of Chromatography, Biomedical Applications, 1990, vol. 532(2), pp. 237… [cited by applicant]
Supplementary European Search Report for Application No. EP10829122, mailed on Feb. 25, 2013, 8 pages. [cited by applicant]
The New Agilent 6530 Accurate-Mass Quadrupole TOF LC/MS System, Agilent Measurement Journal, Issue six, 2008. [cited by applicant]
Thevis M., et al., “Mass Spectrometric Determination of Insulins and Their Degradation Products in Sports Drug Testing,” Mass Spectrometry Reviews, 2008, vol. 27 (1), pp. 35-50. [cited by applicant]
Thomas A., et al., “Determination of IGF-1 and IGF-2, Their Degradation Products and Synthetic Analogues in Urine by LC-MS/MS,” Analyst, 2011, vol. 136 (5), pp. 1003-1012. [cited by applicant]
Thomas A., et al., “Mass Spectrometric Determination of Gonadotrophin-Releasing Hormone (Gnrh) In Human Urine for Doping Control Purposes by Means of LC-ESI-MS/MS,” Journal of Mass Spectrometry, 2008, vol. 43 (7), pp. 9… [cited by applicant]
TOF MS Resolution and Mass Measurement Accuracy, Washington University of St. Lewis, School of Medicine [Online], 2013. Retrieved from the Internet:[ http://msr.dom.wustl.edu/tof-ms-resolution-mass-measurement-accuracy/… [cited by applicant]
Valenzano K., et al., “Biophysical and Biological Properties of Naturally Occurring High Molecular Weight Insulin-like Growth Factor II Variants,” The Journal of Biological Chemistry, 1997, vol. 272(8), pp. 4804-4813. [cited by applicant]
Wadensten H., et al., “Purification and Characterization of Recombinant Human Insulin-Like Growth Factor II (IGF-II) Expressed As a Secreted Fusion Protein in [cited by applicant]
Watson J., et al., “Urinary Insulin-like Growth Factor 2 Identifies the Presence of Urothelial Carcinoma of the Bladder,” BJU International, Blackwell Science, 2008, vol. 103(5), pp. 694-697. [cited by applicant]
Wilkinson R., et al., Expression, Purification, and in Vitro Characterization of Recombinant Salmon Insulin-like Growth Factor-II, Protein Expression and Purification, 2004, vol. 35 (2), pp. 334-343. [cited by applicant]
Wright Jr., G.L., et al., “Proteinchip Surface Enhanced Laser Desorption/Ionization (SELDI) Mass Spectrometry: A Novel Protein Biochip Technology for Detection of Prostate Cancer Biomarkers in Complex Protein Mixtures,”… [cited by applicant]
Written Opinion for Application No. PCT/US10/55518, mailed on Jan. 14, 2011, 6 Pages. [cited by applicant]
Xiao J., et al., “Mass Spectrometric Determination of ILPR G-Quadruplex Binding Sites in Insulin and IGF-2,” Journal of the American Society for Mass Spectrometry, 2009, vol. 20(11), pp. 1974-1982. [cited by applicant]
Zimmer D., et al., “Comparison of Turbulent-Flow Chromatography with Automated Solid-Phase Extraction in 96-Well Plates and Liquid-Liquid Extraction Used As Plasma Sample Preparation Techniques for Liquid Chromatography… [cited by applicant]